The Evolution of Berkshire Hathaway’s Healthcare Thesis
To understand why the Merck & Co. story unfolded the way it did, we have to look at how Buffett historically viewed the entire healthcare space. For decades, the Omaha-based investment vehicle steering wheel remained pointedly directed away from complex biotech operations and clinical trial dependencies. Why? Because the underlying mechanics of drug discovery—the binary outcomes of Phase 3 trials and regulatory approval processes—clashed violently with the core tenets of value investing. Buffett likes predictability; pharmaceutical pipelines are the absolute antithesis of that trait.
The Brief Love Affair with the Pharma Basket Strategy
Everything changed in the third quarter of 2020. Amid a global pandemic that upended macroeconomic assumptions, Berkshire blindsided the market by deploying roughly $6 billion into a diversified basket of prominent pharmaceutical players. This wasn't a sniper shot on a single undervalued enterprise; rather, it was a broad sector bet that spread capital across Merck, AbbVie, Bristol Myers Squibb, and a smaller slice of Pfizer. The logic seemed sound to outsiders who assumed Berkshire was capitalizing on a structurally depressed sector possessing inelastic consumer demand. Yet, the experiment proved remarkably short-lived.
A Swift Departure and the Admission of So-So Conviction
By the time the third-quarter 13F filing dropped in late 2021, the entire Merck position had been erased from Berkshire’s ledger. It was a glaring case of institutional buyer's remorse that Buffett himself subtly addressed during subsequent shareholder meetings. He conceded that the firm had waded into a sector where they lacked deep, specialized insight—admitting he felt "kind of so-so" about the basket and wasn't wildly comfortable holding it over a multi-decade horizon. When you operate with hundreds of billions in equity, holding a massive position you feel lukewarm about is a recipe for underperformance, which explains the aggressive liquidation strategy.
The Structural Anatomy of Berkshire's Merck Allocation and Eventual Exit
Let's look closely at the precise numbers because the sheer speed of this trade is highly uncharacteristic of the classic Berkshire playbook. Berkshire initially bought approximately 22.4 million shares of Merck stock in Q3 2020, establishing a meaningful foothold at an average estimated cost basis of $81.70 per share. They doubled down slightly in the fourth quarter of 2020, aggressively accumulating another 6.29 million shares to bring the total peak position to nearly 29 million shares, which carried a market value exceeding $2.3 billion. But the momentum stalled out immediately as the new calendar year commenced.
Dissecting the Systematic Trimming Process
Instead of sitting on the asset for ten years, the investment team—whether led by Buffett himself or his trusted lieutenants, Ted Weschler and Todd Combs—began methodically hacking away at the position. In the first quarter of 2021, Berkshire unloaded 10.8 million shares, followed swiftly by an 8.7 million share reduction in the second quarter. The final execution occurrred in Q3 2021, when the remaining 9.16 million shares were dumped entirely into the open market at an average closing price of $76.05. Where it gets tricky is calculating the exact profit or loss; while they lost a small amount of capital on the final tranches due to a sliding share price, dividend payouts and early tranches mitigated the damage to roughly a break-even event.
Why the Traditional Warren Buffett Moat Framework Failed Here
The primary reason for this hasty retreat comes down to the elusive nature of a competitive advantage in modern biopharma. Buffett requires a durable moat—a structural barrier like Coca-Cola's global distribution network or Apple’s ecosystem lock-in—that protects a business from aggressive competitors. Merck certainly boasts a magnificent asset in its blockbusting oncology drug, Keytruda, which generates billions in quarterly revenue and dominates the cancer treatment landscape. But what happens when the patent cliff approaches in 2028? The existential dread of patent expirations means a pharma company must continuously reinvent itself, a treadmill dynamic that does not align with Berkshire's preferred style of effortless compounding.
Evaluating Berkshire Hathaway's Modern Institutional Holdings
If you pull up Berkshire’s most recent 13F filing from May 2026, the absence of Merck stock highlights a broader philosophical shift back toward familiar territory. The portfolio remains top-heavy, dominated by massive, cash-generating fortresses that command immense pricing power in their respective markets. Apple still sits comfortably at the top of the mountain representing 21.99% of managed assets, flanked closely by long-time consumer staples and financial juggernauts. Is it surprising that a firm seeking ultimate predictability prefers credit card networks and sugary beverages over oncology pipelines? Honestly, it's unclear to many rookie retail investors why Buffett would pass on high-margin drug companies, but seasoned market participants know he detests sudden regulatory interventions or clinical failures.
Consider the core makeup of the current portfolio concentration as of early 2026:
* Apple Inc. (AAPL): Still anchoring the portfolio at an impressive 21.99% weight. * American Express Co. (AXP): Holding strong at 17.43% as a prime example of brand equity. * The Coca-Cola Co. (KO): The legendary 400,000,000 share stake sits untouched at 11.56%. * Bank of America Corp. (BAC): Sitting at 9.52% despite recent strategic trimmings by management. * Chevron Corp. (CVX): A commanding 6.64% allocation highlighting a renewed love affair with old-school fossil fuels.Alternative Healthcare Bets and the Rising Influence of Ted and Todd
While Merck stock was cast aside, it would be a gross oversimplification to state that Berkshire has abandoned the healthcare sector entirely. The reality is far more nuanced, reflecting a changing of the guard within the Omaha offices. We have to remember that Buffett has given co-investment managers Ted Weschler and Todd Combs authority over billions of dollars, and their fingerprints are all over the current portfolio's non-traditional allocations. For instance, Berkshire continues to maintain a substantial, highly concentrated position in DaVita Inc., a specialized kidney dialysis provider that functions more like a sticky healthcare utility than a volatile drug developer.
The Shift Toward Healthcare Utilities and Royalties
Instead of gambling on which molecular compound will successfully clear FDA scrutiny, Berkshire’s team has gravitated toward businesses that extract toll-booth style revenues from the industry. A prime example was their historical interest in Royalty Pharma, an enterprise that doesn't actually discover drugs but rather buys up royalty streams of already-approved, cash-flowing medical treatments. People don't think about this enough: you can participate in the financial upside of life-saving medicine without exposing your capital to the devastating binary risk of a failed clinical trial. That changes everything for a value investor looking to minimize downside risk while still capturing secular tailwinds.
Common mistakes and misconceptions about Berkshire’s pharma plays
The "Buffett bought it" fallacy
Investors frequently assume every single line item in the Berkshire Hathaway portfolio carries the direct, personal blessing of the Oracle of Omaha. Does Warren Buffett own Merck stock with his own personal capital, or did he pull the trigger himself? Not necessarily. The problem is that the public routinely conflates Buffett’s personal decisions with those of his brilliant co-portfolio managers, Todd Combs and Ted Weschler. These two lieutenants manage billions independently. When Berkshire dips its toes into large-cap pharmaceuticals, it frequently bears the distinct tactical fingerprints of Combs or Weschler rather than the traditional, ultra-long-term consumer moat strategy favored by Buffett himself. If you buy a drug stock simply because it showed up on a 13F filing, you are gambling on an ownership structure you might not fully comprehend.
Chasing the ghost of 13F filings
But regulatory filings are, by their very nature, financial archaeology. Because the SEC grants institutional asset managers a 45-day grace period to report their holdings after the quarter ends, retail traders are always looking through a rearview mirror. Did Warren Buffett own Merck stock yesterday? Perhaps. Does he own it today? That is a completely different question. Except that people treat these quarterly updates like real-time trading signals, rushing to mimic a position that Berkshire might already be aggressively liquidating. This lag creates a dangerous trap for momentum chasers who mistake institutional rotation for a permanent endorsement.
The hidden reality of Berkshire’s revolving pharma door
The quick-flip strategy that stunned Wall Street
Let's be clear: Berkshire Hathaway is legendary for its "our favorite holding period is forever" mantra, which explains why its sudden, aggressive foray into major pharmaceutical companies during late 2020 caught the market completely off guard. The conglomerate built massive positions in a basket of global healthcare giants, acquiring roughly $5.7 billion in pharmaceutical equities across several names, including a substantial multi-million-share stake in Merck. Yet, the real shockwave hit when they abruptly reversed course just quarters later. This was not a classic compounding play; it was a short-term relative value arbitrage execution. Why the sudden change of heart? The healthcare sector faces relentless, structural headwinds ranging from patent cliffs to legislative pricing pressures, causing Berkshire to quickly reallocate capital toward massive energy bets and massive technology infrastructure.
Frequently Asked Questions
When did Berkshire Hathaway completely liquidate its Merck position?
Berkshire Hathaway initiated its massive stake in the pharmaceutical heavyweight during the third quarter of 2020, but the romance was exceptionally short-lived. By the third quarter of 2021, regulatory filings confirmed that the conglomerate had completely dumped its remaining shares. This rapid exit occurred alongside the liquidation of other healthcare giants like AbbVie and Bristol Myers Squibb, representing a massive multi-billion dollar capital rotation. During its peak holding period, Berkshire controlled over 9.1 million shares of Merck, an investment valued at roughly $700 million before the swift divestment. As a result: investors who bought in late found themselves holding the bag after the institutional exit.
Why does Berkshire Hathaway historically avoid major drug companies?
The issue remains that the pharmaceutical business model is inherently antithetical to the core investing tenets that made Buffett famous. Drug development requires staggering research and development budgets, where billions are spent on compounds that might ultimately fail late-stage clinical trials. Can anyone truly predict which oncology pipeline will dominate the global market a decade from now? The inherent lack of a predictable, permanent economic moat scares away traditional value investors who demand highly stable cash flows. Consequently, Berkshire prefers predictable consumer monopolies or capital-intensive infrastructure plays over the high-stakes science experiments found in biotech.
How can investors verify what stocks Berkshire currently owns?
The only authoritative method to verify these holdings is by analyzing the official Form 13F filed quarterly with the Securities and Exchange Commission. These documents are made public on the SEC EDGAR database exactly 45 days after the termination of each fiscal quarter. Websites tracking institutional portfolios aggregate this data cleanly, allowing retail investors to inspect every single fluctuation in the conglomerate's massive equity portfolio. However, you must remember that these filings only disclose long equity positions, entirely omitting short positions, foreign listings, or massive cash equivalents. In short, it provides a vital snapshot, but it never tells the whole story.
A definitive verdict on the Oracle's healthcare thesis
Relying on old headlines to determine if Warren Buffett owns Merck shares is a losing proposition for any serious portfolio. The evidence shows that Berkshire's brief love affair with big pharma was a fleeting tactical maneuver rather than a foundational shift in doctrine. We believe that retail investors should stop blindly copying institutional moves that are already obsolete by the time they hit the public domain. Chasing the ghosts of past filings reveals a fundamental misunderstanding of how dynamically modern conglomerates reallocate their capital. If you want to invest like Berkshire, you need to focus on businesses with unbreakable competitive moats rather than trying to front-run their short-term healthcare trades. Stop looking for salvation in Buffett's discarded pharmacy receipts and start analyzing the actual underlying balance sheets yourself.